{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T09:24:44Z","timestamp":1788341084093,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Educational Program of Saitama Medical University for Research Mind Promotion of Undergraduates","award":["UH34-01"],"award-info":[{"award-number":["UH34-01"]}]},{"DOI":"10.13039\/501100004200","name":"Stiftelsen Olle Engkvist Byggm\u00e4stare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004200","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Spanish State Research Agency and EDR Funds","award":["SAF-2017-88126-R"],"award-info":[{"award-number":["SAF-2017-88126-R"]}]},{"name":"Spanish State Research Agency and EDR Funds","award":["PID2019-106404RB-100"],"award-info":[{"award-number":["PID2019-106404RB-100"]}]},{"name":"Spanish State Research Agency and EDR Funds","award":["201129918"],"award-info":[{"award-number":["201129918"]}]},{"DOI":"10.13039\/501100003086","name":"Basque Government","doi-asserted-by":"crossref","award":["IT1512\/22"],"award-info":[{"award-number":["IT1512\/22"]}],"id":[{"id":"10.13039\/501100003086","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s43440-023-00448-6","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T11:49:34Z","timestamp":1673610574000},"page":"266-275","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Agonistic properties of a series of psychotropic drugs at 5-HT1A receptors in rat and human brain membranes determined by [35S]GTP\u03b3S binding assay"],"prefix":"10.1007","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1792-028X","authenticated-orcid":false,"given":"Yuji","family":"Odagaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Mikami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7913-6714","authenticated-orcid":false,"given":"J. Javier","family":"Meana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9941-012X","authenticated-orcid":false,"given":"Luis F.","family":"Callado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5143-2442","authenticated-orcid":false,"given":"Jes\u00fas A.","family":"Garc\u00eda-Sevilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5736-373X","authenticated-orcid":false,"given":"Dasiel Oscar","family":"Borroto-Escuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8491-4288","authenticated-orcid":false,"given":"Kjell","family":"Fuxe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"448_CR1","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1146\/annurev.med.60.042307.110802","volume":"60","author":"M Berger","year":"2009","unstructured":"Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med. 2009;60:355\u201366.","journal-title":"Annu Rev Med"},{"key":"448_CR2","doi-asserted-by":"publisher","first-page":"471","DOI":"10.31887\/DCNS.2010.12.4\/ycharnay","volume":"12","author":"Y Charnay","year":"2010","unstructured":"Charnay Y, L\u00e9ger L. Brain serotonergic circuitries. Dialogues Clin Neurosci. 2010;12:471\u201387.","journal-title":"Dialogues Clin Neurosci"},{"key":"448_CR3","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1124\/pr.118.015552","volume":"73","author":"NM Barnes","year":"2021","unstructured":"Barnes NM, Ahern GP, Becamel C, Bockaert J, Camilleri M, Chaumont-Dubel S, et al. International union of basic and clinical pharmacology. CX. Classification of receptors for 5-hydroxytryptamine; Pharmacology and function. Pharmacol Rev. 2021;73:310\u2013520.","journal-title":"Pharmacol Rev"},{"key":"448_CR4","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.biopsych.2009.03.012","volume":"66","author":"E Akimova","year":"2009","unstructured":"Akimova E, Lanzenberger R, Kasper S. The serotonin-1A receptor in anxiety disorders. Biol Psychiatry. 2009;66:627\u201335.","journal-title":"Biol Psychiatry"},{"key":"448_CR5","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.euroneuro.2015.12.039","volume":"26","author":"J Kaufman","year":"2016","unstructured":"Kaufman J, DeLorenzo C, Choudhury S, Parsey RV. The 5-HT1A receptor in major depressive disorder. Eur Neuropsychopharmacol. 2016;26:397\u2013410.","journal-title":"Eur Neuropsychopharmacol"},{"key":"448_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/026988110101500108","volume":"15","author":"RA Bantick","year":"2001","unstructured":"Bantick RA, Deakin JFW, Grasby PM. The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol. 2001;15:37\u201346.","journal-title":"J Psychopharmacol"},{"key":"448_CR7","first-page":"853","volume":"295","author":"MJ Millan","year":"2000","unstructured":"Millan MJ. Improving the treatment of schizophrenia: focus on serotonin (5-HT)1A receptors. J Pharmacol Exp Ther. 2000;295:853\u201361.","journal-title":"J Pharmacol Exp Ther"},{"key":"448_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.biochi.2018.10.015","volume":"161","author":"PR Albert","year":"2019","unstructured":"Albert PR, Vahid-Ansari F. The 5-HT1A receptor: signaling to behavior. Biochimie. 2019;161:34\u201345.","journal-title":"Biochimie"},{"key":"448_CR9","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.cellsig.2010.03.019","volume":"22","author":"AM Polter","year":"2010","unstructured":"Polter AM, Li X. 5-HT1A receptor-regulated signal transduction pathways in brain. Cell Signal. 2010;22:1406\u201312.","journal-title":"Cell Signal"},{"key":"448_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.brainres.2012.04.032","volume":"1461","author":"C Loane","year":"2012","unstructured":"Loane C, Politis M. Buspirone: what is it all about? Brain Res. 2012;1461:111\u20138.","journal-title":"Brain Res"},{"key":"448_CR11","first-page":"802","volume":"11","author":"A Newman-Tancredi","year":"2010","unstructured":"Newman-Tancredi A. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. Curr Opin Investig Drugs. 2010;11:802\u201312.","journal-title":"Curr Opin Investig Drugs"},{"key":"448_CR12","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/j.1476-5381.2012.02223.x","volume":"168","author":"T Kenakin","year":"2013","unstructured":"Kenakin T. New concepts in pharmacological efficacy at 7TM receptors: IUPHAR review 2. Br J Pharmacol. 2013;168:554\u201375.","journal-title":"Br J Pharmacol"},{"key":"448_CR13","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/j.1440-1681.2007.04595.x","volume":"34","author":"Y Odagaki","year":"2007","unstructured":"Odagaki Y, Toyoshima R. 5-HT1A receptor agonist properties of antipsychotics determined by [35S]GTP\u03b3S binding in rat hippocampal membranes. Clin Exp Pharmacol Physiol. 2007;34:462\u20136.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"448_CR14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1177\/0269881105051526","volume":"19","author":"Y Odagaki","year":"2005","unstructured":"Odagaki Y, Toyoshima R, Yamauchi T. Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTP\u03b3S binding. J Psychopharmacol. 2005;19:235\u201341.","journal-title":"J Psychopharmacol"},{"key":"448_CR15","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1749-6632.1998.tb09009.x","volume":"851","author":"G Bagdy","year":"1998","unstructured":"Bagdy G. Serotonin, anxiety, and stress hormones. Focus on 5-HT receptor subtypes, species and gender differences. Ann NY Acad Sci. 1998;851:357\u201363.","journal-title":"Ann NY Acad Sci"},{"key":"448_CR16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1254\/jphs.FPJ05010X","volume":"98","author":"Y Odagaki","year":"2005","unstructured":"Odagaki Y, Toyoshima R. Detailed pharmacological characterization of 5-HT1A-receptor-mediated [35S]GTP\u03b3S binding in rat hippocampal membranes. J Pharmacol Sci. 2005;98:66\u201376.","journal-title":"J Pharmacol Sci"},{"key":"448_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejphar.2005.07.018","volume":"521","author":"Y Odagaki","year":"2005","unstructured":"Odagaki Y, Toyoshima R. 5-HT1A receptor-mediated G protein activation assessed by [35S]GTP\u03b3S binding in rat cerebral cortex. Eur J Pharmacol. 2005;521:49\u201358.","journal-title":"Eur J Pharmacol"},{"key":"448_CR18","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/bcpt.13183","volume":"124","author":"Y Odagaki","year":"2019","unstructured":"Odagaki Y, Kinoshita M, Ota T, Meana JJ, Callado LF, Garc\u00eda-Sevilla JA. Optimization and pharmacological characterization of receptor-mediated Gi\/o activation in postmortem human prefrontal cortex. Basic Clin Pharmacol Toxicol. 2019;124:649\u201359.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"448_CR19","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1111\/j.1476-5381.2010.00963.x","volume":"161","author":"PG Strange","year":"2010","unstructured":"Strange PG. Use of the GTP\u03b3S ([35S]GTP\u03b3S and Eu-GTP\u03b3S) binding assay for analysis of ligand potency and efficacy at G protein-coupled receptors. Br J Pharmacol. 2010;161:1238\u201349.","journal-title":"Br J Pharmacol"},{"key":"448_CR20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/0166-4328(96)00074-5","volume":"73","author":"GW Price","year":"1996","unstructured":"Price GW, Roberts C, Watson J, Burton M, Mulholland K, Middlemiss DN, et al. Species differences in 5-HT autoreceptors. Behav Brain Res. 1996;73:79\u201382.","journal-title":"Behav Brain Res"},{"key":"448_CR21","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s40263-013-0071-0","volume":"27","author":"P Celada","year":"2013","unstructured":"Celada P, Bortolozzi A, Artigas F. Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS Drugs. 2013;27:703\u201316.","journal-title":"CNS Drugs"},{"key":"448_CR22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","volume":"441","author":"S Jordan","year":"2002","unstructured":"Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002;441:137\u201340.","journal-title":"Eur J Pharmacol"},{"key":"448_CR23","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","volume":"28","author":"DA Shapiro","year":"2003","unstructured":"Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28:1400\u201311.","journal-title":"Neuropsychopharmacology"},{"key":"448_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s00213-006-0621-y","volume":"190","author":"AD Stark","year":"2007","unstructured":"Stark AD, Jordan S, Allers KA, Bertekap RL, Chen R, Mistry Kannan T, et al. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT2A receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology. 2007;190:373\u201382.","journal-title":"Psychopharmacology"},{"key":"448_CR25","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1124\/jpet.114.213793","volume":"350","author":"K Maeda","year":"2014","unstructured":"Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350:589\u2013604.","journal-title":"J Pharmacol Exp Ther"},{"key":"448_CR26","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1124\/jpet.110.167346","volume":"334","author":"T Ishibashi","year":"2010","unstructured":"Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010;334:171\u201381.","journal-title":"J Pharmacol Exp Ther"},{"key":"448_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.euroneuro.2008.11.001","volume":"19","author":"R Ghanbari","year":"2009","unstructured":"Ghanbari R, El Mansari M, Shahid M, Blier P. Electrophysiological characterization of the effects of asenapine at 5-HT1A, 5-HT2A, \u03b12-adrenergic and D2 receptors in the rat brain. Eur Neuropsychopharmacol. 2009;19:177\u201387.","journal-title":"Eur Neuropsychopharmacol"},{"key":"448_CR28","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1021\/jm101459g","volume":"54","author":"B Bang-Andersen","year":"2011","unstructured":"Bang-Andersen B, Ruhland T, J\u00f8rgensen M, Smith G, Frederiksen K, Jensen KG, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011;54:3206\u201321.","journal-title":"J Med Chem"},{"key":"448_CR29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.pharmthera.2014.07.001","volume":"145","author":"C Sanchez","year":"2015","unstructured":"Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther. 2015;145:43\u201357.","journal-title":"Pharmacol Ther"},{"key":"448_CR30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/0269881107082944","volume":"23","author":"M Shahid","year":"2009","unstructured":"Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009;23:65\u201373.","journal-title":"J Psychopharmacol"},{"key":"448_CR31","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00210-006-0041-x","volume":"372","author":"Y Odagaki","year":"2006","unstructured":"Odagaki Y, Toyoshima R. 5-HT-stimulated [35S]guanosine-5\u2019-O-(3-thio)triphosphate binding as an assay for functional activation of G proteins coupled with 5-HT1B receptors in rat striatal membranes. Naunyn Schmiedebergs Arch Pharmacol. 2006;372:335\u201345.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"448_CR32","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s00210-003-0788-2","volume":"368","author":"A Newman-Tancredi","year":"2003","unstructured":"Newman-Tancredi A, Rivet JM, Cussac D, Touzard M, Chaput C, Marini L, et al. Comparison of hippocampal G protein activation by 5-HT1A receptor agonists and the atypical antipsychotics clozapine and S16924. Naunyn Schmiedebergs Arch Pharmacol. 2003;368:188\u201399.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"448_CR33","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.pnpbp.2006.05.007","volume":"30","author":"Y Odagaki","year":"2006","unstructured":"Odagaki Y, Toyoshima R. Dopamine D2 receptor-mediated G protein activation assessed by agonist-stimulated [35S]guanosine 5\u2019-O-(\u03b3-thiotriphosphate) binding in rat striatal membranes. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:1304\u201312.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"448_CR34","first-page":"177","volume-title":"Horizons in neuroscience research","author":"Y Odagaki","year":"2020","unstructured":"Odagaki Y. Receptor-mediated activation of a certain type of G\u03b1 in brain membranes: re-establishment of [35S]GTP\u03b3S binding\/immunoprecipitation assay. In: Costa A, Villalba E, editors. Horizons in neuroscience research, vol. 38. New York, USA: Nova Science Publishers; 2020. p. 177\u2013202."},{"key":"448_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF02245588","volume":"121","author":"J De Vry","year":"1995","unstructured":"De Vry J. 5-HT1A receptor agonists: recent developments and controversial issues. Psychopharmacology. 1995;121:1\u201326.","journal-title":"Psychopharmacology"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-023-00448-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-023-00448-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-023-00448-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T01:21:31Z","timestamp":1680139291000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-023-00448-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["448"],"URL":"https:\/\/doi.org\/10.1007\/s43440-023-00448-6","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,13]]},"assertion":[{"value":"28 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}